October 19, 2011 |
A prenatal blood test that can detect Down syndrome in a fetus in early pregnancy is now available to doctors in 20 U.S. cities, says the developer of the test, Sequenom Inc . The test is a milestone in prenatal testing because it's the first non-invasive way to detect trisomy 21, the most common cause of Down syndrome. Until now, women have had to undergo amniocentesis or chorionic villus sampling, both invasive tests, to detect Down syndrome. A more recent strategy was to combine ultrasound testing with blood tests, but that test required confirmation with amniocentesis or CVS. The blood test measures fetal DNA in the mother's bloodstream.
February 1, 2000 |
San Diego-based biotech company Sequenom Inc. (SQNM) priced 5.25 million shares Monday at $26, above the expected range of $23 to $25, raising $136.5 million. The shares will begin trading today on Nasdaq. Sequenom, whose products to analyze genes are used in clinical trials and to develop drugs, sold 250,000 more shares than expected.
May 30, 2001 |
San Diego-based Sequenom Inc. said Tuesday it will buy Britain's Gemini Genomics for $228 million in stock, part of a wave of consolidation in the emerging genomics industry. Sequenom said the tie-up would combine its genotyping technology platform with Gemini's expertise in population genetics, expanding their potential for disease-gene discovery.
May 21, 2002 |
The annual meeting of the nation's cancer specialists, one of the largest and most closely watched medical gatherings of the year, often gives biotechnology stocks a fillip. Not this year. More bad news from ImClone Systems Inc., whose drug Erbitux failed in a mid-stage trial to halt or reverse the course of head and neck cancer, sent its shares tumbling $2.29, or 17%, to $11.12 on Monday.
February 9, 2000 |
The new biotech rush is on. Is it a prescription for disaster? With biotechnology stocks sizzling, start-ups are scrambling to get in on the action. According to Prudential Securities analyst Caroline Copithorne, 11 biotechs have filed already this year to make initial public offerings. That compares with 11 biotech companies for the entire 1999 calendar year. Genomics stocks have led the biotech sector's charge. Affymetrix Inc.
July 6, 2012 |
Scientists can now sequence the entire genome of a fetus from samples of a pregnant woman's blood, several recent studies have shown. It will come as no surprise that bioethicists are plenty interested in these developments and the benefits and thorny issues they will raise. The technology -- and the issues -- are discussed at length in a commentary this week in the journal Nature Medicine by Diana Bianchi of the Mother Infant Research Institute at Tufts Medical Center. Because a pregnant woman's blood carries pieces of fetal DNA, researchers can devise tests to tell with a high degree of certainty whether the fetus carries extra chromosomes (as an extra chromosome 21 in Down syndrome, for example)